Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cantor Fitzgerald
Covington
McKesson
Healthtrust
Daiichi Sankyo
Chubb
Boehringer Ingelheim
Baxter

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,419,973

« Back to Dashboard

Which drugs does patent 7,419,973 protect, and when does it expire?

Patent 7,419,973 protects TEFLARO and is included in one NDA.

This patent has fifteen patent family members in thirteen countries.
Summary for Patent: 7,419,973
Title:Phosphonocephem compound
Abstract:A cephem compound (particularly its crystal) represented by the formula [I], wherein X is CH.sub.3COOH, CH.sub.3CH.sub.2COOH or CH.sub.3CN, and n is 0 to 5, is useful as an antibacterial agent (particularly anti-MRSA agent) and shows superior quality such as high solid stability, possible long-term stable preservation and the like. ##STR00001##
Inventor(s): Ishikawa; Tomoyasu (Shiga, JP), Hashiguchi; Shohei (Osaka, JP), Iizawa; Yuji (Kyoto, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:11/063,715
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,419,973
Patent Claim Types:
see list of patent claims
Composition; Compound; Formulation;

Drugs Protected by US Patent 7,419,973

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-001 Oct 29, 2010 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-002 Oct 29, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,419,973

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-247966Aug 10, 2000
Japan2000-354959Nov 21, 2000

Non-Orange Book US Patents Family Members for Patent 7,419,973

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,906,055 Phosphonocephem compound ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Fuji
Express Scripts
Merck
Mallinckrodt
Medtronic
Queensland Health
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.